Hematocrit Test Devices Market Size

The global hematocrit test devices market size was valued at USD 3.8 billion in 2024 and is expected to exhibit growth at a CAGR of 4.4% from 2025 to 2034 period. The high market growth can be attributed to the increasing prevalence of blood disorders, growing geriatric population, and advancements in point-of-care testing, among other contributing factors.

Moreover, the rising prevalence of blood disorders including anemia, polycythemia, and sickle cell disease increases the demand for hematocrit testing. For instance, according to the World Health Organization (WHO), anemia affects about 1.62 billion people globally, representing 24.8% of the population. Similarly, the Centers for Disease Control and Prevention (CDC) reports that sickle cell disease affects approximately 100,000 Americans, with 1 in 365 Black or African American births having the condition. Hence, these medical conditions require continuous monitoring of hematocrit levels, which drives the need for accurate and accessible testing equipment.

Hematocrit test devices are diagnostic tools used to measure the proportion of red blood cells (RBCs) in a person blood. This test is essential for diagnosing various conditions such as anemia, dehydration, and polycythemia. These devices typically provide rapid, accurate results by analyzing blood samples, and they come in various forms, including analyzers, meters, and point-of-care testing devices.